Cargando…

Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients

We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddow, Lewis J., Laverick, Rosanna, Daskalopoulou, Marina, McDonnell, Jeffrey, Lampe, Fiona C., Gilson, Richard, Speakman, Andrew, Antinori, Andrea, Balestra, Pietro, Bruun, Tina, Gerstoft, Jan, Nielsen, Lars, Vassilenko, Anna, Collins, Simon, Rodger, Alison J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902513/
https://www.ncbi.nlm.nih.gov/pubmed/28144792
http://dx.doi.org/10.1007/s10461-017-1683-z
_version_ 1783314767385985024
author Haddow, Lewis J.
Laverick, Rosanna
Daskalopoulou, Marina
McDonnell, Jeffrey
Lampe, Fiona C.
Gilson, Richard
Speakman, Andrew
Antinori, Andrea
Balestra, Pietro
Bruun, Tina
Gerstoft, Jan
Nielsen, Lars
Vassilenko, Anna
Collins, Simon
Rodger, Alison J.
author_facet Haddow, Lewis J.
Laverick, Rosanna
Daskalopoulou, Marina
McDonnell, Jeffrey
Lampe, Fiona C.
Gilson, Richard
Speakman, Andrew
Antinori, Andrea
Balestra, Pietro
Bruun, Tina
Gerstoft, Jan
Nielsen, Lars
Vassilenko, Anna
Collins, Simon
Rodger, Alison J.
author_sort Haddow, Lewis J.
collection PubMed
description We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤−1 in at least 2 out of 5 cognitive domains. Participants’ mean age was 45.8 years; 84% male; 87% white; 56% university educated; median CD4 count 550 cells/mm(3); 89% on antiretroviral therapy. 156 (35%) participants had NCI, among whom 26 (17%; 5.8% overall) reported a decline in activities of daily living. Prevalence of NCI was lower in those always able to afford basic needs (adjusted prevalence ratio [aPR] 0.71, 95% confidence interval [CI] 0.54–0.94) or with a university education (aPR 0.72, 95% CI 0.54–0.97) and higher in those with severe depressive symptoms (aPR 1.53, 95% CI 1.09–2.14) or a significant comorbid condition (aPR 1.40, 95% CI 1.03–1.90).
format Online
Article
Text
id pubmed-5902513
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-59025132018-04-24 Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients Haddow, Lewis J. Laverick, Rosanna Daskalopoulou, Marina McDonnell, Jeffrey Lampe, Fiona C. Gilson, Richard Speakman, Andrew Antinori, Andrea Balestra, Pietro Bruun, Tina Gerstoft, Jan Nielsen, Lars Vassilenko, Anna Collins, Simon Rodger, Alison J. AIDS Behav Original Paper We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤−1 in at least 2 out of 5 cognitive domains. Participants’ mean age was 45.8 years; 84% male; 87% white; 56% university educated; median CD4 count 550 cells/mm(3); 89% on antiretroviral therapy. 156 (35%) participants had NCI, among whom 26 (17%; 5.8% overall) reported a decline in activities of daily living. Prevalence of NCI was lower in those always able to afford basic needs (adjusted prevalence ratio [aPR] 0.71, 95% confidence interval [CI] 0.54–0.94) or with a university education (aPR 0.72, 95% CI 0.54–0.97) and higher in those with severe depressive symptoms (aPR 1.53, 95% CI 1.09–2.14) or a significant comorbid condition (aPR 1.40, 95% CI 1.03–1.90). Springer US 2017-01-31 2018 /pmc/articles/PMC5902513/ /pubmed/28144792 http://dx.doi.org/10.1007/s10461-017-1683-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Haddow, Lewis J.
Laverick, Rosanna
Daskalopoulou, Marina
McDonnell, Jeffrey
Lampe, Fiona C.
Gilson, Richard
Speakman, Andrew
Antinori, Andrea
Balestra, Pietro
Bruun, Tina
Gerstoft, Jan
Nielsen, Lars
Vassilenko, Anna
Collins, Simon
Rodger, Alison J.
Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients
title Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients
title_full Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients
title_fullStr Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients
title_full_unstemmed Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients
title_short Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients
title_sort multicenter european prevalence study of neurocognitive impairment and associated factors in hiv positive patients
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902513/
https://www.ncbi.nlm.nih.gov/pubmed/28144792
http://dx.doi.org/10.1007/s10461-017-1683-z
work_keys_str_mv AT haddowlewisj multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT laverickrosanna multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT daskalopouloumarina multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT mcdonnelljeffrey multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT lampefionac multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT gilsonrichard multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT speakmanandrew multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT antinoriandrea multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT balestrapietro multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT bruuntina multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT gerstoftjan multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT nielsenlars multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT vassilenkoanna multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT collinssimon multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT rodgeralisonj multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients
AT multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients